191 related articles for article (PubMed ID: 26159838)
21. Diclofenac/biodegradable polymer micelles for ocular applications.
Li X; Zhang Z; Li J; Sun S; Weng Y; Chen H
Nanoscale; 2012 Aug; 4(15):4667-73. PubMed ID: 22732776
[TBL] [Abstract][Full Text] [Related]
22. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation.
Rahman Z; Zidan AS; Khan MA
Int J Pharm; 2010 Nov; 400(1-2):49-58. PubMed ID: 20801200
[TBL] [Abstract][Full Text] [Related]
23. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
24. Novel biodegradable blend matrices for controlled drug release.
Lin M; Meng S; Zhong W; Li Z; Du Q; Tomasik P
J Pharm Sci; 2008 Oct; 97(10):4240-8. PubMed ID: 18271038
[TBL] [Abstract][Full Text] [Related]
25. Formulation optimization of solid dispersion of mosapride hydrochloride.
Kim HJ; Lee SH; Lim EA; Kim JS
Arch Pharm Res; 2011 Sep; 34(9):1467-75. PubMed ID: 21975808
[TBL] [Abstract][Full Text] [Related]
26. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release.
Lu Y; Yu Y; Tang X
J Pharm Sci; 2007 Dec; 96(12):3252-62. PubMed ID: 17721936
[TBL] [Abstract][Full Text] [Related]
27. Investigation of PLLA/PCL blends and paclitaxel release profiles.
Can E; Udenir G; Kanneci AI; Kose G; Bucak S
AAPS PharmSciTech; 2011 Dec; 12(4):1442-53. PubMed ID: 22038476
[TBL] [Abstract][Full Text] [Related]
28. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(epsilon-caprolactone) blends for tissue engineering applications in the form of hollow fibers.
Chiono V; Ciardelli G; Vozzi G; Sotgiu MG; Vinci B; Domenici C; Giusti P
J Biomed Mater Res A; 2008 Jun; 85(4):938-53. PubMed ID: 17896770
[TBL] [Abstract][Full Text] [Related]
29. Preparation and characterization of silk fibroin hydrogel as injectable implants for sustained release of Risperidone.
Ebrahimi A; Sadrjavadi K; Hajialyani M; Shokoohinia Y; Fattahi A
Drug Dev Ind Pharm; 2018 Feb; 44(2):199-205. PubMed ID: 28956466
[TBL] [Abstract][Full Text] [Related]
30. Long-lasting anti-platelet activity of cilostazol from poly(ε-caprolactone)-poly(ethylene glycol) blend nanocapsules.
Gomes MLS; da Silva Nascimento N; Borsato DM; Pretes AP; Nadal JM; Novatski A; Gomes RZ; Fernandes D; Farago PV; Zanin SMW
Mater Sci Eng C Mater Biol Appl; 2019 Jan; 94():694-702. PubMed ID: 30423756
[TBL] [Abstract][Full Text] [Related]
31. Melt electrospinning vs. solution electrospinning: A comparative study of drug-loaded poly (ε-caprolactone) fibres.
Lian H; Meng Z
Mater Sci Eng C Mater Biol Appl; 2017 May; 74():117-123. PubMed ID: 28254275
[TBL] [Abstract][Full Text] [Related]
32. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier.
Khan AW; Kotta S; Ansari SH; Sharma RK; Ali J
Drug Dev Ind Pharm; 2015 May; 41(5):772-9. PubMed ID: 24669978
[TBL] [Abstract][Full Text] [Related]
33. Novel biodegradable polyesters. Synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles.
Bikiaris D; Karavelidis V; Karavas E
Molecules; 2009 Jul; 14(7):2410-30. PubMed ID: 19633613
[TBL] [Abstract][Full Text] [Related]
34. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics.
Karavas E; Georgarakis E; Bikiaris D
Eur J Pharm Biopharm; 2006 Aug; 64(1):115-26. PubMed ID: 16675210
[TBL] [Abstract][Full Text] [Related]
35. Protein release from electrospun nonwovens: improving the release characteristics through rational combination of polyester blend matrices with polidocanol.
Puhl S; Ilko D; Li L; Holzgrabe U; Meinel L; Germershaus O
Int J Pharm; 2014 Dec; 477(1-2):273-81. PubMed ID: 25445519
[TBL] [Abstract][Full Text] [Related]
36. Physicochemical characterization of solid dispersions of three antiepileptic drugs prepared by solvent evaporation method.
Douroumis D; Bouropoulos N; Fahr A
J Pharm Pharmacol; 2007 May; 59(5):645-53. PubMed ID: 17524229
[TBL] [Abstract][Full Text] [Related]
37. Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone.
Mohammed KA; Ibrahim HK; Ghorab MM
Drug Deliv; 2016; 23(1):297-306. PubMed ID: 24833273
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of bio-compatibility via specific interactions in polyesters modified with a bio-resourceful macromolecular ester containing polyphenol groups.
Yen KC; Mandal TK; Woo EM
J Biomed Mater Res A; 2008 Sep; 86(3):701-12. PubMed ID: 18041717
[TBL] [Abstract][Full Text] [Related]
39. Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins.
Huatan H; Collett JH; Attwood D; Booth C
Biomaterials; 1995 Nov; 16(17):1297-303. PubMed ID: 8573667
[TBL] [Abstract][Full Text] [Related]
40. Development of oral solid self-emulsifying lipid formulations of risperidone with improved in vitro dissolution and digestion.
Kazi M; Al-Qarni H; Alanazi FK
Eur J Pharm Biopharm; 2017 May; 114():239-249. PubMed ID: 28159721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
